Supreme Court Rejects CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising fight with Natera, leaving a lower court ruling in place.
The U.S. Supreme Court on Monday refused to take up CareDx's appeal in a false-advertising lawsuit involving rival diagnostics company Natera, effectively closing the door on CareDx's bid to overturn an earlier court decision that went against it. The high court's denial of certiorari means the lower court's ruling stands without further federal review.
The legal clash between CareDx and Natera centers on competing claims in the organ-transplant monitoring diagnostics market, where both companies offer tests designed to detect early signs of organ rejection. False-advertising disputes of this kind often hinge on whether marketing claims about clinical performance or test accuracy cross a legal line, making them especially consequential in the medical-testing sector where physicians rely on promotional materials to inform treatment decisions.
Read more Berkshire Hathaway Seen as Defensive Bet Amid Market Risks →
For Natera, the Supreme Court's refusal to engage is a clear legal victory that shields the company from renewed litigation risk at the nation's highest judicial level. CareDx, by contrast, now faces the full weight of the lower court's findings with no federal appellate path remaining on this particular issue. Investors in both companies were watching the docket closely given the competitive stakes in the rapidly growing transplant diagnostics space.
The outcome could influence how aggressively diagnostics firms market their products against direct competitors, knowing that false-advertising claims can survive appeal all the way to the Supreme Court's doorstep. Analysts may reassess the competitive positioning of both CareDx and Natera in light of the ruling's finality.
Continue reading at Yahoo Finance.
